Ironwood Pharmaceuticals (IRWD) Receiving Somewhat Favorable Press Coverage, Report Finds

News coverage about Ironwood Pharmaceuticals (NASDAQ:IRWD) has trended somewhat positive on Saturday, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Ironwood Pharmaceuticals earned a news impact score of 0.06 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 45.9612483844721 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

IRWD has been the subject of several recent analyst reports. Berenberg Bank initiated coverage on Ironwood Pharmaceuticals in a research report on Thursday, April 19th. They issued a “buy” rating and a $25.00 price target for the company. Wells Fargo set a $18.00 price target on Ironwood Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, April 9th. Zacks Investment Research lowered Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, April 18th. BidaskClub lowered Ironwood Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Monday, February 5th. Finally, ValuEngine raised Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, April 9th. One analyst has rated the stock with a sell rating, six have issued a hold rating and six have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $18.60.

Ironwood Pharmaceuticals opened at $18.08 on Friday, according to MarketBeat Ratings. Ironwood Pharmaceuticals has a one year low of $12.89 and a one year high of $19.94. The stock has a market capitalization of $2.82 billion, a P/E ratio of -19.44 and a beta of 1.07. The company has a quick ratio of 4.40, a current ratio of 4.42 and a debt-to-equity ratio of -21.52.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings data on Tuesday, May 1st. The biotechnology company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.06). Ironwood Pharmaceuticals had a negative return on equity of 2,073.20% and a negative net margin of 34.12%. The business had revenue of $69.16 million during the quarter, compared to the consensus estimate of $78.65 million. During the same quarter in the previous year, the business posted ($0.33) earnings per share. Ironwood Pharmaceuticals’s quarterly revenue was up 32.6% compared to the same quarter last year. sell-side analysts expect that Ironwood Pharmaceuticals will post -0.62 EPS for the current year.

In related news, CFO Gina Consylman sold 3,594 shares of Ironwood Pharmaceuticals stock in a transaction dated Wednesday, February 21st. The stock was sold at an average price of $14.66, for a total value of $52,688.04. Following the completion of the sale, the chief financial officer now directly owns 59,125 shares in the company, valued at approximately $866,772.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders sold a total of 6,728 shares of company stock valued at $97,732 over the last quarter. 7.63% of the stock is owned by corporate insiders.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout in adults under the ZURAMPIC and DUZALLO names.

Insider Buying and Selling by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply